Therapeutic Drug Monitoring (TDM)
Also known as: Drug Level Monitoring, Serum Drug Level Monitoring, Clinical Pharmacokinetic Monitoring, İlaç Düzeyi İzlemi
Therapeutic Drug Monitoring (TDM) is a clinical pharmacokinetic practice in which drug concentrations are measured in a patient's blood to guide individualized dosing. It applies principally to drugs with narrow therapeutic windows—where the margin between efficacy and toxicity is small—such as aminoglycosides, vancomycin, cyclosporine, and antiepileptics. Developed as a formal discipline in the 1980s, TDM integrates measured concentrations with pharmacokinetic modeling to calculate patient-specific dose regimens.
Key highlights
- Directly accounts for inter-patient variability in drug absorption, distribution, and elimination
- Reduces the incidence of both therapeutic failure and concentration-dependent toxicity
- Provides an objective, quantitative basis for dose individualization supported by established pharmacokinetic theory
- Applicable across diverse therapeutic areas including antimicrobials, immunosuppressants, antiepileptics, and oncology agents
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
TDM is indicated for drugs with narrow therapeutic indices, highly variable pharmacokinetics, or serious consequences of under- or over-dosing. Key assumptions are that a defined therapeutic range exists in the literature and that plasma concentration correlates with clinical effect at the site of action. It is unsuitable when no established target range exists, when the drug acts irreversibly, or when rapid feedback loops make concentration-guided dosing impractical. Bayesian forecasting software and population pharmacokinetic models are common algorithmic alternatives that extend the basic proportional approach.
Strengths & limitations
- Directly accounts for inter-patient variability in drug absorption, distribution, and elimination
- Reduces the incidence of both therapeutic failure and concentration-dependent toxicity
- Provides an objective, quantitative basis for dose individualization supported by established pharmacokinetic theory
- Applicable across diverse therapeutic areas including antimicrobials, immunosuppressants, antiepileptics, and oncology agents
- Requires accurate knowledge of sample timing relative to the dose; timing errors propagate directly into parameter estimates
- Assumes a stable relationship between plasma and effect-site concentrations, which may not hold during acute physiological changes
- Effective target ranges are not established for all drugs, limiting the scope of applicability
- Resource-intensive: requires laboratory infrastructure, trained clinicians, and coordinated sample collection workflows
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
Why does sample timing matter so much in TDM?
Drug concentrations change continuously across the dosing interval following the exponential decay described by C(t) = (F·D/Vd)·e^(−ke·t). A sample taken even 30 minutes earlier or later than intended can shift the estimated concentration by a clinically meaningful amount, leading to incorrect parameter estimation and an inappropriate dose adjustment. Standardized trough sampling just before the next dose minimizes this source of error for most drugs.
What is a therapeutic window and how is it determined?
The therapeutic window is the concentration range bounded below by the minimum effective concentration (below which the drug is unlikely to work) and above by the minimum toxic concentration (above which adverse effects become unacceptable). It is established through population-level clinical studies correlating plasma concentrations with efficacy and toxicity endpoints, and published in guidelines or drug-specific dosing literature. The window is population-based and may need adjustment for individual patient characteristics.
When is Bayesian forecasting preferred over simple proportional dose adjustment?
Bayesian forecasting incorporates a prior population pharmacokinetic model together with the patient's observed concentrations to generate a posterior estimate of individual parameters. It is preferred when only a single poorly timed sample is available, when the drug exhibits complex multi-compartment kinetics, or when the patient's characteristics (renal impairment, obesity, critical illness) deviate substantially from the standard population. Simple proportional adjustment is adequate for drugs with one-compartment linear kinetics and well-timed samples.
Sources
- 1.Spector, R., Park, G. D., Johnson, G. F., & Vesell, E. S. (1988). Therapeutic drug monitoring. Clinical Pharmacology & Therapeutics, 43(4), 345–353.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 2). Therapeutic Drug Monitoring. ScholarGate. https://scholargate.app/pharmacometrics/therapeutic-drug-monitoring